{"name":"Debiopharm International SA","slug":"debiopharm-international-sa","ticker":"","exchange":"","domain":"debiopharminternational.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Debio 4126","genericName":"Debio 4126","slug":"debio-4126","indication":"Advanced solid tumors (Phase 3 development)","status":"phase_3"},{"name":"Debio 4326","genericName":"Debio 4326","slug":"debio-4326","indication":"Advanced solid tumors (phase 3 development)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Vancomycin IV","genericName":"Vancomycin IV","slug":"vancomycin-iv","indication":"Serious or life-threatening infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA)","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Placebo Tablet or Capsule","genericName":"Placebo Tablet or Capsule","slug":"placebo-tablet-or-capsule","indication":"Clinical trial control arm (non-therapeutic use)","status":"marketed"}]}],"pipeline":[{"name":"Vancomycin IV","genericName":"Vancomycin IV","slug":"vancomycin-iv","phase":"marketed","mechanism":"Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption.","indications":["Serious or life-threatening infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA)","Bacterial endocarditis","Clostridium difficile-associated diarrhea and colitis","Staphylococcal enterocolitis","Gram-positive infections in penicillin-allergic patients"],"catalyst":""},{"name":"Debio 4126","genericName":"Debio 4126","slug":"debio-4126","phase":"phase_3","mechanism":"Debio 4126 is a selective inhibitor of mitochondrial complex I that disrupts energy metabolism in cancer cells.","indications":["Advanced solid tumors (Phase 3 development)"],"catalyst":""},{"name":"Debio 4326","genericName":"Debio 4326","slug":"debio-4326","phase":"phase_3","mechanism":"Debio 4326 is a selective inhibitor of mitochondrial complex I that disrupts energy metabolism in cancer cells.","indications":["Advanced solid tumors (phase 3 development)"],"catalyst":""},{"name":"Placebo Tablet or Capsule","genericName":"Placebo Tablet or Capsule","slug":"placebo-tablet-or-capsule","phase":"marketed","mechanism":"A placebo tablet or capsule contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect.","indications":["Clinical trial control arm (non-therapeutic use)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNOVhzRmZHRlZPc1BvVkkwYlBlY2J4anFScTBBd3dfSF91NGFzS0NnV0lJbi0xRm5UVWdLU1dLcUpCUld5TXl3TV9kRnEtXzVOTDVPVWhVa2JFanFxZjBRNFpOMEwtVjN4bnBodUR3cnRlRGpBZjJPQjJrejFhY3kxSWhPUGlSZFUxeHhDeDdCWk9oUXJYY1ZR?oc=5","date":"2026-02-23","type":"pipeline","source":"Yahoo Finance","summary":"Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight - Yahoo Finance","headline":"Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerg","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPajFfbGdqdWlqVFFYUjB5WUxxb2xweF9iMmg2bW1sbTJNSWtkRkJTbkV5aHNKWFFvMTJkdGtYZ01rZ3pmQ3AyeFJlZG1wZENVZl9TRUoxTEY1MTNsZTExcU5oQ09VOUR0YXRQeXZ6dGd6aEhoUW1Lck5WOFMza3IwdlBlQlM2VXhWSVNEYXp2TjBwN1dxYlVWZWp3ZTlKT0JIYUhTakVJUTNVUQ?oc=5","date":"2025-02-18","type":"deal","source":"BioWorld News","summary":"APAC deals abound: Lilly taps Advancell, Olix; Genome draws Ellipses - BioWorld News","headline":"APAC deals abound: Lilly taps Advancell, Olix; Genome draws Ellipses","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQTkwwbEZzZEJldktncEpsVk1oTUl4X1V0VkR6UXNzVEZXMGozZ1V5V1BEMnRIT2N1SnJja2x2dDRRRVR1SGFSQ0gwcnRFOV8tdmZITHBhRnhJcEkwRkJsdUhhS2kzdUFFM0pocm9DSE1GRlZWQzQ5dUJnT2dnWTR1MW9IYm9qMlJweGhnU1VuT21sNzRPOF95MmVvbERaLVlYV3NaNUpqLWFRRWFkSUNfN2toTGpFNzBzLTY3aXlkNm1NZWFaaGhjb3dvcjVCQk1TUVJ2TTJUMllEcXdSMUlGT3hXanBKUEU?oc=5","date":"2024-10-28","type":"pipeline","source":"Pharmaceutical Technology","summary":"Transforming pharmaceutical R&D: the impact of digital technologies on drug discovery and development - Pharmaceutical Technology","headline":"Transforming pharmaceutical R&D: the impact of digital technologies on drug discovery and development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gJBVV95cUxPYlJ4SUM0QW9kcmdkcGVjS2k5X2dWb3RqaTRSZGdvdEY4N3B5TVpZdGhDWXpoX1h6SnZfeU9HR0RjNzlKWWRJMUpVT09sWHVxUWdreWtYdk5zR0E4V3RTNndMNW1Wa1R6cWRRWDEyVmtoeFVZY25hdU42SDhaR2UyVERDZjNPWVBjUTMwZDUtaUVxc054NVV1c1pFZWRxYVVDWlBuaHdWSU1KUlZhcHpsdWJQNklHdW10VEhYSFlTNTNkYl9aNXRrWUJ3c0N2cDFxVVczTUJJU0Z0azNSWlVoRkx6bVMxREI1Ulp3MVBDTWN3RnAzQUlCbWpQd2xFTXlqbzNWWW9WbG01ODJEYU4wQURoMU1DQXZLQkhtbUVpVGxsdEVfY2RLSjNKUFoxeWg4dDY2Nm45SE1DODZ5TjJWMHRpNERCVTRObS1rZmVaVk04cU51dDh0akdfOXFTTlQySGc?oc=5","date":"2024-10-14","type":"pipeline","source":"globenewswire.com","summary":"Peptide Therapeutics Industry Report 2024, Featuring - globenewswire.com","headline":"Peptide Therapeutics Industry Report 2024, Featuring","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNaklUTzNPTURFU2NkUC00Njl5U0w4NUNLUTRORHBka1Buei1MTTZidzBuLXhCZk14cUt2SXFleF9RUlBNQ3VFcUlIWWxHb3UxbzZydDY4WG1Od3Q5UWtvdnFXT2lsejlkYm0yWnA2OEhqUmoycklscjVRX05CdWVObzNNZ3JGSjY5NDVPcFVROGl0TXlkaHR1ODlKQ19OMTJ2Um40S0dMamdxaGZmLXFweWVrUzRIZHRP?oc=5","date":"2024-06-25","type":"trial","source":"MarketWatch","summary":"Germany’s Merck Group shares drop 10% after scrapping trial of promising cancer drug - MarketWatch","headline":"Germany’s Merck Group shares drop 10% after scrapping trial of promising cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPMk5PNEVBeG1PYjBvMUwtcDlocWpOMHF4bm96Z1I3ekZmdXN2ZFBpM2JETHI2U3FKbjB0UExZaWdaOHVDTG9iT1dzU1dtMzR2UVNzZUlacThNb2hyZkV6MG5YVXdpNjkxU3p5SkpZU1ZxbkItbjM2LTF4WWNrQkNVWjBGaXo0cHM3RkNLUHJ0LUwySEVvaTVBdFBpaWdrMVNwZE5XUjBSMGlidlBjcmxv?oc=5","date":"2024-06-25","type":"trial","source":"Clinical Trials Arena","summary":"Merck KGaA abandons Phase III trial for $1.08bn head & neck cancer drug - Clinical Trials Arena","headline":"Merck KGaA abandons Phase III trial for $1.08bn head & neck cancer drug","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-06-25","type":"trial","source":"Express Pharma","summary":"Merck discontinues Phase III TrilynX Study in locally advanced head and neck cancer - Express Pharma","headline":"Merck discontinues Phase III TrilynX Study in locally advanced head and neck cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOeU1KOVVQVXhxd1Nob0cxbVh6YmpJTTNkdFl3OGI3SlB2WmR1Yi1XaDRpRVVMTUpKdkM2S3djSEhlb1dIYjBXOHJpcnZVWE9HSDhTdno0MHVSY2gzbFotOXRjd01KWnJjMnM0TGpXQ3J3SlBuYm0wWjQyZVFCUUtKZFd2c3lwQkMxc3hHQjZHdGJxdG1TLUhPZjBPUnhkN3R5RXJNbG1DbDZzUS1xb2JKMFNMbjNHci0xMG10azZONkdNV2M3VnpMSVlB?oc=5","date":"2023-10-27","type":"pipeline","source":"BioSpectrum Asia","summary":"Japan's Yakult transfers marketing authorisation of cancer drug Elplat to Takata - BioSpectrum Asia","headline":"Japan's Yakult transfers marketing authorisation of cancer drug Elplat to Takata","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQeGp1bXNaelVFdDdlUm9pNGtWeU5qNVBpYncybjFoaWJTRngwMWN1M1kyY3lkdmJuUXhfREpLN1dmR3B0LXZEZkhHV0ZLYzlkX096WkdXUWlpTWFabUpLVjZlSHZrZ1RQTnNzUUFfNTY0el95dmZZMlJZcjRRV2ZRMnItOHByZ2NvTWJwZl9nSldXUTMwaHBJaWxTdVF0Yk00WmJFVmdPTmpMV0dNUjM0dDNSX0NKMTNBTmZwanBLX3ZPN1BmY0FHNXRFaV91T1NBWHF3Y09B?oc=5","date":"2023-09-29","type":"pipeline","source":"EU-Startups","summary":"Debiopharm Innovation Fund: A €141+ million initiative to transform pharma R&D and cancer care innovation - EU-Startups","headline":"Debiopharm Innovation Fund: A €141+ million initiative to transform pharma R&D and cancer care innovation - EU","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE5FMFA4dm8zOW9hVXpTVlROcXBySUF0UjlzN2NyMHhuYWltclZXLVFySWRRQ1I5dUo5M3ZHUGVhcW5qcGhRV2F5cVo1Z1NwX0pjVVdxb3QxMjVDdzh1eUlWQjh2QQ?oc=5","date":"2022-04-11","type":"pipeline","source":"Presseportal.ch","summary":"DEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ADVANCEMENTS AT AACR 2022 FOR NOVEL CANCER ... - Presseportal.ch","headline":"DEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ADVANCEMENTS AT AACR 2022 FOR NOVEL CANCER ...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQYktlTkdEM3JBeW02YmFGODduTWhiWVY5bk9iSXVrZ2E2YUJZbXFaVDc0cEllemktdkhpMVA1b1pfbGUzMDd2d1lGOU45dTVwZEpBYXo0akFtTHRvcEl4VkZNcHRNbGxBc0NvbXRlNk53blhnd0U3TzFrYzFaeDlvNXZYeG9tSHVnYnowb05RN3FnOGRjdndIbkNjQXJEbjhEZ0NiUjQ2c09KOWxUd0RHYXdZSQ?oc=5","date":"2021-07-20","type":"trial","source":"Clinical Leader","summary":"The Right Precision Medicine Partner Is Essential For Trials And Patients - Clinical Leader","headline":"The Right Precision Medicine Partner Is Essential For Trials And Patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOSXdXNjVoT2xrTEdpYXZab2IzVmNJUHVJMWsyR1JuVmtwMTVHaEQxcktXNjFFZ0VSZ2llTDRpakw5VFFQclY3Q0g1VUpvNjVDcWJfTGgxYTBNRV9OcnlsM0hTWFAxX1dWSnd3NGZ4RGZVNjJ0VlBMa1R6WEgzb0FQbzZsXzRTcGhETVFyUzhMQQ?oc=5","date":"2017-03-20","type":"regulatory","source":"European Pharmaceutical Review","summary":"Debiopharm’s triptorelin 6-month formulation receives EU approval - European Pharmaceutical Review","headline":"Debiopharm’s triptorelin 6-month formulation receives EU approval","sentiment":"positive"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":2,"phase_3":2},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}